Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus
Infection with Marburg virus (MARV), the causative agent of Marburg virus disease (MVD), results in haemorrhagic disease and high case fatality rates (>40%) in humans. Despite its public health relevance, there are no licensed vaccines or therapeutics to prevent or treat MVD. A vesicular stomatit...
Saved in:
| Main Authors: | Cecilia A. Prator, Brianna M. Dorratt, Kyle L. O’Donnell, Justin Lack, Amanda N. Pinski, Stacy Ricklefs, Craig A. Martens, Ilhem Messaoudi, Andrea Marzi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2252513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model
by: Sandra L. Bixler, et al.
Published: (2025-02-01) -
Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
by: Paige Fletcher, et al.
Published: (2023-12-01) -
Marburg Virus Disease: A Narrative Review
by: Arash Letafati, et al.
Published: (2025-05-01) -
Marburg Fever in Equatorial Guinea, Tanzania, and Rwanda: Global Crisis in Public Health Service or Standard Situation?
by: M. V. Supotnitskiy, et al.
Published: (2025-02-01) -
Outbreak of Marburg Virus Disease, Equatorial Guinea, 2023
by: Stephanie Ngai, et al.
Published: (2025-05-01)